Skip to main content

Table 3 Univariate and multivariate Cox models of OS

From: Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

 

Univariate analysis

Multivariate analysis

HR

95% CI

P value

HR

95% CI

P value

Age

1.042

0.999–1.086

0.054

1.019

0.962–1.079

0.522

BMI

1.013

0.943–1.088

0.730

   

HR status

2.019

0.942–4.328

0.071

2.104

0.978–4.529

0.057

Menopausal status

2.133

1.081–4.210

0.029

1.768

0.670–4.665

0.250

cN status

3.921

1.624–9.471

0.002

4.060

1.672–9.859

0.002

cT status

1.680

0.857–3.295

0.131

1.1516

0.763–3.011

0.235

Zoledronic acid

0.448

0.218–0.919

0.029

0.468

0.226–0.967

0.040

  1. Bold values indicate that P < 0.05OS overall survival, HR hazard ratio, CI confidence interval, BMI body mass index
  2. the italicized data have a significance of > 0.05